Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, is thrilled to unveil its groundbreaking product, Cellgenic Lyophilized Exosomes – The Regen Series. We believe this product is set to revolutionize orthopedic and pain management applications, offering a remarkable potential for tissue regeneration in damaged areas of the body. Derived from human umbilical cord mesenchymal stem cells, Cellgenic Lyophilized Exosomes is a multifaceted solution that holds promise in addressing a wide range of ailments.

Cellgenic Lyophilized Exosomes contain a synergistic blend of essential components, including peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation-reducing agents. These elements not only facilitate tissue regeneration but also make this product an exceptional option for skin revitalization. By utilizing this remarkable product, individuals may experience reduced pain levels.

A Revolutionary Product

Cellgenic Lyophilized Exosomes demonstrate unparalleled versatility and efficacy. Notably, this product requires no special storage conditions, enabling customers to utilize it conveniently at full capacity. Designed to combat inflammation and facilitate tissue repair, this targeted solution can significantly alleviate chronic pain, providing relief to those who have struggled to find effective solutions.

The exosome technology utilized in this product involves the freeze-drying of extracellular vesicles (EVs), which are kept separate from the mesenchymal stem cell cultures expanded in the laboratory. The Lyophilized Exosomes are then reconstituted with saline in front of the patient, just before use. This approach has proven to be highly effective in reducing inflammation and managing pain.

Global Stem Cells Group Remains a Leader in the Industry

One of the things that has helped set Global Stem Cells Group apart from the competition is their willingness to think in innovative ways that others simply do not. For example, the brand-new Lyophilized Exosome product can be shipped anywhere around the world without refrigeration. This allows for the possibility of getting it out to the places that truly need it without the burdensome ordeal of having to maintain the medication at a certain temperature. This is a problem for many medications, but GSCG has made sure that its products are more versatile than that.

Growing Faster Than Ever Before

Global Stem Cells Group has a lot going for it as far as its growth trajectory is concerned. They already have multiple offices around the globe, and they are always looking to expand their outreach by opening offices wherever it is prudent to do so. We believe the new product, Lyophilized Exosomes – The Regen Series, is set to strengthen GSCG’s position as a global leader in the regenerative and restorative medicine space for now and long into the future.

Benito Novas, CEO of Global Stem Cells Group, expressed his excitement about the company’s growth and stated, “Our goal at Global Stem Cells Group is to develop the most effective regenerative products on the market. Our new product line of lyophilized exosomes is a testament to our commitment to developing cutting-edge products with great clinical utility.”

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.